The Cold Spring Harbor Laboratory Cancer Center is led by Dr. Bruce Stillman, Dr. Scott Lowe and Dr. Nicholas Tonks. Dr, Stillman has been the Director of the CSHL Cancer Center since 1992. As Director of the Cancer Center, he is responsible for overall direction, strategic planning and raising funds to support the research and Shared Resources. He is assisted in oversight of the Cancer Center by two Deputy Directors, Dr. Scott Lowe and Dr. Nicholas Tonks. Dr. Lowe was appointed Deputy Director for Research of the Cancer Center in 2001. In this position, he is primarily responsible for oversight of the cancer research and programs, strategic planning and recruitment of new members to the Cancer Center. Dr. Nicholas Tonks was appointed Deputy Director for Shared Resources for the Cancer Center in 2007. He supervises all the Shared Resource leaders, provides leadership on funding and is responsible for ongoing periodic Shared Resource review. These three senior leaders are committed to maintaining and improving CSHL as a premier center for cancer research.

Public Health Relevance

The Director and Deputy Directors of the Cold Spring Harbor Laboratory Cancer Center oversee a dynamic and vibrant cancer research program and provide leadership for 32 scientists in three research programs who are committed to understanding the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-27
Application #
8712146
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
27
Fiscal Year
2014
Total Cost
$226,761
Indirect Cost
$132,617
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7:
Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67
Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60
Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804
Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201
Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605
Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8:
Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:
Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801

Showing the most recent 10 out of 380 publications